Abstract: The potency of a recombinant human erythropoietin (rhEPO) pharmaceutical preparation was evaluated by the normocythaemic mice bioassay using standardized and randomized protocol of European ...

President Trump's new Executive Order takes aim at high drug prices. Here are three that are poised to profit regardless of DC politics. Unlock your all-in-one trading dashboard with real-time ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more. From STAT’s Andrew Joseph: Lars Fruergaard ...

Regeneron Pharmaceuticals secured a victory in an antitrust case that accused Amgen Inc. of anticompetitive bundling practices, as a jury awarded the company nearly $407 million in damages Thursday. A ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware ...

Department of Chemical Engineering and Analytical Chemistry, Institute for Research on Nutrition and Food Safety (INSA·UB), University of Barcelona, Martí i Franquès 1-11, Barcelona 08028, Spain ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen ...

Teprotumumab approved as first targeted treatment for thyroid eye disease The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...